Executive Vice President Donghyun Kim of RudaCure presented the 疗效 of the drug RCI001 currently under development at the 欧洲干眼学会 annual conference held in 波兰克拉科夫, which aims to address the 未满足的需求 of 干眼症 patients in 欧洲. This year's event was held from June 19th to 21st.
The conference is held annually and served as an opportunity to demonstrate the excellence of RCI001 to many 欧洲an 干眼 researchers.
Additionally, during the 2025 BIO-USA period, RudaCure shared the RCI001 development progress with Thea of 法国 and Santen of 日本, and discussed future development issues.